A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer

Gynecologic Oncology
Lindsey E MinionKrishnansu S Tewari

Abstract

To evaluate the cost-effectiveness of bevacizumab in recurrent/persistent and metastatic cervical cancer using recently reported updated survival and toxicology data. A Markov decision tree based on the Gynecologic Oncology Group 240 randomized trial was created. The 2013 MediCare Services Drug Payment Table and Physician Fee Schedule provided costs. In the 5-year model subjects transitioned through the following states: response, progression, minor complications, severe complications, and death. Patients experiencing a health utility per month according to treatment effectiveness were calculated. Because cervical cancer survival is measured in months rather than years, results were reported in both quality adjusted cervical cancer life months and years (QALmonth, QALY), adjusted from a baseline of having advanced cervical cancer during a month. The estimated total cost of therapy with bevacizumab is approximately 13.2 times that for chemotherapy alone, adding $73,791 per 3.5months (0.29year) of life gained, resulting in an incremental cost-effectiveness ratio (ICER) of $21.083 per month of added life. The ICER increased to $5775 per month of added life and $24,597/QALmonth ($295,164/QALY) due to the smaller difference in QALmo...Continue Reading

References

Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Sep 13, 2006·British Journal of Cancer·A LloydJ Watkins
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Dec 2, 2008·Nature Reviews. Drug Discovery·Michael Goodman
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkLynda D Roman
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkDavid Cella
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Sep 18, 2010·Journal of Evaluation in Clinical Practice·Jignesh J PatelAnthony P Morreale
Mar 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David E CohnJ Michael Straughn
Apr 30, 2011·The New England Journal of Medicine·UNKNOWN CATT Research GroupGlenn J Jaffe
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators
Aug 8, 2012·ClinicoEconomics and Outcomes Research : CEOR·Chun-Ru Chien, Ya-Chen Tina Shih
Feb 8, 2013·American Journal of Clinical Oncology·Tamer RefaatWilliam Small
May 22, 2013·Drug Discovery Today·Hans C EbbersHuub Schellekens
Nov 2, 2013·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Oreto Ruiz-MilloN Victor Jimenez-Torres
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Feb 21, 2014·The New England Journal of Medicine·Krishnansu S TewariBradley J Monk
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
Apr 30, 2014·International Journal of Technology Assessment in Health Care·Lachlan StandfieldPaul Scuffham

❮ Previous
Next ❯

Citations

Jan 23, 2016·Expert Opinion on Biological Therapy·Nicolò BizzarriSimone Ferrero
Jul 28, 2015·American Journal of Obstetrics and Gynecology·Krista S Pfaendler, Krishnansu S Tewari
Jul 7, 2015·Gynecologic Oncology·Katherine C FuhJohn K Chan
Oct 18, 2015·The Lancet Oncology·Krishnansu S Tewari
Oct 18, 2016·Expert Review of Anticancer Therapy·Lindsey E Minion, Krishnansu S Tewari
Dec 10, 2017·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A Godoy-OrtizA Sánchez-Muñoz
Feb 23, 2017·American Journal of Clinical Oncology·Dustin B MandersDebra L Richardson
Aug 18, 2018·The Cancer Journal·Krista S PfaendlerKrishnansu S Tewari
Jul 26, 2018·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Hyun-Jin ChoiByoung-Gie Kim
Aug 18, 2017·American Journal of Clinical Oncology·Lavanya H Palavalli ParsonsJayanthi S Lea
Apr 19, 2019·ESMO Open·Chakor Vora, Sudeep Gupta
Feb 6, 2020·Journal of Public Health Policy·Rachael P BehlerNasim S Sabounchi
Jul 19, 2017·Journal of Global Oncology·Bishal Gyawali, Mahesh Iddawela
Sep 27, 2020·Journal of Medical Imaging and Radiation Oncology·Kanisa RongsriyamVichan Lorvidhaya
Aug 11, 2020·Dose-response : a Publication of International Hormesis Society·Wanjun TaoYixin Wang
Aug 21, 2020·American Journal of Obstetrics and Gynecology·Miranda BlancoJason D Wright
Mar 5, 2021·The Cochrane Database of Systematic Reviews·Yunhai ChuaiAiming Wang
May 2, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Dinesh Kumar ChellappanKamal Dua

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.